ClinicalTrials.gg
RecruitingNCT07419464Updated Apr 27, 2026

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

A Phase 2 interventional study of 5-Fluorouracil in Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma and Recurrent Squamous Cell Carcinoma of the Head and Neck, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing fluorouracil in Squamous Cell Carcinoma of Head and Neck — 2 open to participants now, 5 under way, 1 of them phase 3. Fluorouracil · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
21st of 36
46 · median 68
Started
2026
the only one that year
Phase 2
19 of 38
2 open now
Registered
38th of 38
by date
Lead sponsor
2 of 38
Washington University School of Medicine

Among the 38 studies testing fluorouracil in Squamous Cell Carcinoma of Head and Neck, this one is the 21st largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2026, is one of 19 in phase 2, and was the 38th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

2 of the 38 studies testing fluorouracil in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing fluorouracil in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patients with RM-HNSCC. Eligible patients for this trial will have previously received platinum and PD-1 inhibitor therapy. The experimental regimen (Arm 1) will comprise the two days every two weeks (2D-Q2W) regimen of 5-FU. The standard regimen (Arm 2) will consist of the four days every three weeks (4D-Q3W) regimen of 5-FU. The primary hypotheses is that each regimen of 5-FU will result in an ORR of 10% of greater assessed by RECIST v1.1 criteria. The study will also describe treatment-related AEs assessed by CTCAE v5.0, dose interruptions, discontinuations, and modifications in each regimen.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
  • Metastatic Squamous Cell Carcinoma
  • Recurrent Squamous Cell Carcinoma of the Head and Neck

Keywords

  • 5-FU
  • HNSCC
  • RM-HNSCC
  • Oral cavity
  • Oropharynx
  • Larynx
  • Hypopharynx
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed:

    • RM-HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx, OR
    • p16+ (HPV-related) level 2-3 neck node and unknown primary site, OR
    • Second primary HNSCC in a previously radiated field not amenable to curative-intent surgery and/or re-radiation.
  • per 1.1.
  • Previously treated with platinum-based chemotherapy, RM disease within 6 months of definitive cisplatin + radiation therapy (DCisRT) or post-operative adjuvant cisplatin + radiation therapy (POACisRT) OR progressive disease on or after or intolerance to platinum agent given for RM disease.
  • Previously treated with inhibitor, RM disease within 6 months of PD-1 inhibitor given as part of curative-intent therapy OR progressive disease on or after PD-1 inhibitor given for RM disease OR intolerance to prior PD-1 inhibitor in the curative or setting.
  • At least 18 years of age
  • performance status ≤ 2
  • Adequate bone marrow and organ function as defined below:

    • ≥ 1.0 K/cumm
    • ≥ 100 K/cumm
    • ≥ 8.0 g/dL
    • Total ≤ 1.5 x IULN (for subjects with Gilbert's disease ≤ 3 x IULN)
    • (SGOT)/ALT(SGPT)/Alkaline Phosphatase (ALP) ≤ 3.0 x IULN. For subjects with documented bone metastasis, ALP ≤ 5.0 x IULN.
    • Serum creatinine \<3 mg/dL or > 30 mL/min by Cockcroft- Gault.
  • The effects of 5-FU on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate prior to study entry, for the duration of study participation, and for 30 days after last dose of 5-FU
  • Recovery to baseline or ≤ grade 1 from AEs due to prior therapy, unless AEs are clinically nonsignificant and/or stable on supportive therapy (e.g., physiological replacement of ). Low-grade or controlled toxicities such as alopecia, ≤ grade 2 hypomagnesemia, or ≤ grade 2 neuropathy are permitted.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Prior 5-FU given to treat RM-HNSCC.
  • Prior or concurrent whose natural history has the potential to interfere with the safety or efficacy assessment of the regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
  • Currently receiving any other investigational agents.
  • RM or incurable second primary SCC of cutaneous, nasopharynx, paranasal/nasal/sinus origin.
  • DPYD deficiency (poor or intermediate metabolizer) as determined by next generation sequencing through blood or saliva (results of historical testing are accepted).
  • Severe hepatic impairment ( C) or history of or C.
  • Patients with untreated . Patients with treated brain metastases are allowed if post-treatment brain-imaging after CNS-directed therapy shows no evidence of progression.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-FU or other agents used in the study.
  • Pregnant and/or breastfeeding. Women of must have a negative urine pregnancy test within 14 days of study registration.
  • -infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Arm 1: 5-Fluorouracil (5-FU) 2D-Q2W

    Patients randomized to Arm 1 will receive 5-FU as a 400mg/m2 bolus followed by 2,400 mg/m2 continuous intravenous infusion (CIVI) over a 46 hour time period every 2 weeks on Day 1-2 and Days 15-16. Each cycle is 28 days.

    Drug: 5-Fluorouracil

  • Active comparator
    Arm 2: 5-Fluorouracil (5-FU) 4D-Q3W

    Patients randomized to Arm 2 will receive 5-FU as a 1000g/m2/day continuous intravenous infusion (CIVI) over 4 days every 3 weeks on Day 1-4. Each cycle is 21 days.

    Drug: 5-Fluorouracil

Interventions

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose modifications or reductions are determined by patient's tolerability to the drug.

    Also known as: Adrucil, 5-FU

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    * ORR, defined as CR and PR per RECIST v1.1. * Complete Response (CR): Disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Start of treatment through completion of treatment (estimated time up to 4 months)

Secondary outcomes

  1. Incidence of patients requiring a dose reduction due to treatment related adverse events (TRAEs)

    Time frame: Start of treatment through completion of treatment (estimated time up to 4 months)

  2. Incidence of patients requiring a dose interruption or delay due to treatment related adverse events (TRAEs)

    Time frame: Start of treatment through completion of treatment (estimated time up to 4 months)

  3. Incidence of patients requiring treatment discontinuation due to treatment related adverse events (TRAEs)

    Time frame: Start of treatment through completion of treatment (estimated time up to 4 months)

  4. Daily dose intensity

    Daily dose intensity will be measured as the average daily dose/m2 of 5-FU administered in the treatment interval for each regimen (Days 1-2 and Days 15-16 for Arm 1 and Days 1-4 for Arm 2).

    Time frame: Start of treatment through completion of treatment (estimated time up to 4 months)

  5. Overall Adverse Events (AEs) by grade (3, 4, and 5) and type

    Adverse events are classified and graded by CTCAE v5.0.

    Time frame: Start of treatment to 28 days after completion of treatment (estimated time up to 5 months)

  6. Number of adverse events of specific interest (AESI)

    Adverse events of special interest are as follows: diarrhea, mucositis, palmar-plantar erythrodysesthesia (Hand-Foot Syndrome) (PPE/HRS), neutropenia, and thrombocytopenia. Adverse events are classified by CTCAE v5.0.

    Time frame: Start of treatment through 28 days after completion of treatment (estimated time up to 5 months)

  7. Number of treatment-related deaths

    Time frame: Start of treatment through 28 days after completion of treatment (estimated time up to 5 months)

  8. Duration of Response (DoR)

    * DoR is defined as the duration from the onset of first response (CR + PR) to disease progression or death for any reason * Complete Response (CR): Disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From time criteria is met for CR or PR through 3 years after completion of treatment (up to 3 years and 4 months)

  9. Progression-free survival (PFS)

    PFS is defined as the time from the date of treatment start to progression or death, which occurs first. The alive patients without progression are censored at the last follow-up.

    Time frame: Start of treatment through 3 years after completion of treatment (up to 3 years and 4 months)

  10. Overall survival (OS)

    OS is defined as the time from the start of treatment to the date of death, censored at the last follow-up otherwise.

    Time frame: Start of treatment through 3 years after completion of treatment (up to 3 years and 4 months)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Christine Auberle, MD · Contactauberlec@wustl.edu · 314-747-1459
    • Christine Auberle, MD · Principal investigator
    • Douglas Adkins, MD · Sub investigator
    • Brendan Knapp, MD · Sub investigator
    • Peter Oppelt, MD · Sub investigator
    • Jesse Zaretsky, MD, PhD · Sub investigator
    • Esther Lu, PhD · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 27 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 19, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2031
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07419464
Collaborators
The Joseph Sanchez Foundation
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Apr 21, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Apr 27, 2026

Study contacts

Christine Auberle, MD
Contact
auberlec@wustl.edu
314-747-1459
Christine Auberle, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorouracil

Start the discussion